We have used a two-transgene tetracycline system to reversibly express oncogenic H-Ras V12G in mouse skin and primary keratinocytes culture using the bovine keratin 5 promoter. Induction of H-Ras V12G expression in skin at 30 days after birth causes epidermal basal cell hyperplasia, an eruption of keratinous cysts and loss of hair follicles by 3 weeks. Subsequent H-Ras V12G deinduction for 3 days results in massive apoptosis in the non-HRas V12G -expressing stroma as well as in the suprabasal cells of the epidermis. Several procaspases such as CASP3, 1a, 5 and 12 disappeared, whereas the pro-apoptotic proteins AIF, Bax and Fas ligand were induced in H-Ras V12G de-induction skin. This process is followed by a wave of cell division at 14 days as hair follicles regrew, returning to near normal histology and skin appearance by 30 days. Using Kinetworks TM multi-immunoblotting screens, the phosphorylation status of 37 proteins and expression levels of 75 protein kinases in the skin were determined in three samples: (i) wild-type skin, (ii) hyperplastic H-Ras V12G -expressing skin and (iii) skin where H-Ras V12G expression was suppressed for 7 days. Following H-Ras V12G induction, 16 kinases were increased over 2-fold, and 2 kinases were reduced over 50%. This included increased phosphorylation of both known downstream H-Ras V12G targets and unknown H-Ras V12G targets. After H-Ras V12G suppression, many but not all protein changes were reversed. These results from skin and primary keratinocytes are organized to reflect the molecular events that cause the histological changes observed. These proteomic changes identify markers that may mediate the oncogenic addiction paradigm.
Introduction
Expression in transgenic mice of either oncogenic H-Ras or K-Ras results in both cellular proliferation and tumorigenesis (1) producing a variety of mouse models for human disease including follicular adenoma (2) , melanoma (3) and Costello syndrome (4) . Several investigators have constitutively expressed Ras or its oncogenic forms in the skin and observed both hyperproliferation of the epidermis and subsequent formation of squamous cell carcinomas (5), demonstrating that activated Ras is sufficient to produce a malignant phenotype. Expression of oncogenic Ras in different compartments of the skin produces different results. Suprabasal epithelial cell expression using the keratin 10 promoter causes hyperplasia and papillomas that slowly progress into carcinomas (6) , whereas expression in the hair follicle compartment that contains skin stem cells using the keratin 5 promoter caused papillomas that readily convert into carcinomas (5) .
Mutations in each Ras gene have been detected at high frequency in many human cancers, with frequencies ranging from 10 to 90% (7) , with different cancers types having reproducible mutations in specific Ras genes. Mouse models of skin chemical carcinogenesis indicate that oncogenic mutations in Ras play a central role in skin tumor development (8) , suggesting that the oncogenic properties of Ras are similar in mice and humans.
There are three Ras proto-oncogenes in mammals (1) that have GTPase activity and function to activate kinases (9) whose downstream targets are transcription factors culminating in changes in gene expression (10) . Oncogenic Ras is able to transform cells in culture by both promoting cell growth and inhibiting anoikis (11) , a term for cell death induced in tissue culture when cells fail to make proper cell-cell and cell-stromal interactions (12) . The inhibition of anoikis is critical for the ability of Ras-transformed cells to grow in soft agar (13) .
Ras-signaling pathways underlie cellular transformation as demonstrated by transfection of either Ras or its downstream targets (14) . However, in epidermal keratinocytes, conflicting data have been presented, indicating that Ras promotes proliferation and suppress differentiation (15) or does the opposite, such as cell cycle arrest and induction of apoptosis (16) 
More recently, oncogenic H-Ras V12G has been reversibly expressed in melanocytes to show that it is continually needed to maintain the malignant phenotype (17) . Similar observations were made for the reversible expression of Myc (18) and a mutant epidermal growth factor (EGF) receptor (19) . These observations have been conceptualized to suggest that cancer cells develop a dependence or ''addiction'' to the continued activity of over-expressed oncogenes for maintenance of their malignant phenotype (20, 21) . However, the molecular correlates of this poorly understood phenomenon have not been reported.
To identify such molecular correlates, we have reversibly expressed H-Ras V12G in the basal layer of the mouse epidermis using the K5 promoter. Here we show that the expression of H-Ras V12G induces hyperplasia in the skin by 3 weeks and subsequent de-induction results in a return to normal skin and histology by 30 days. To help determine the mechanism of tumor regression, we have examined changes in the concentration of over 100 phosphoproteins and proteins that occur in the skin when H-Ras V12G expression is activated and subsequently suppressed. The reversibility by H-Ras V12G induction and de-induction was also observed in primary keratinocytes. These proteomic changes that occur as H-Ras V12G is de-induced may be potential therapeutic targets.
Skin histology, measurement of cell proliferation and apoptosis Skin tissues were fixed in 10% neutral buffered formalin (NBF) overnight, transferred to 95% Et-OH and embedded in paraffin. Six micrometer sections were cut and stained with hematoxylin and eosin. To label dividing cells, mice were sacrificed 60 min after a single intraperitoneal injection of a sterile solution of BrdU (Sigma, Saint Louis, MO; 10 mg/ml in phosphate-buffered saline, 50 mg/kg of body weight). Skin sections were treated for 30 min at 37°C with 2N HCl in phosphate-buffered saline containing 0.5% Triton X-100, rinsed in sodium tetraborate buffer (0.1 M, pH 8.5) and stained using an antiBrdU antibody (DAKO diagnostics, Angel Drove Ely, UK). Apoptosis was determined in tissue sections using an ApopTag kit (Chemicon, Temecula, CA 92590).
Western blot analysis
Protein extracts were made from whole skin or primary keratinocytes using RIPA lysis buffer containing 1% sodium dodecyl sulfate, 1% Nonidet P-40 and 0.5% sodium deoxycholate and cocktail of protease inhibitors. Western blots of lysates were performed on 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and probed with a-146 anti-H-Ras monoclonal antibodies (Quality Biotech, Lamden, NJ), anti-Bax polyclonal antibodies and anti-vascular endothelial growth factor (VEGF) polyclonal antibodies (Santa Cruz Biotechnology), differentiation-related antibodies (K1, K10, involucrin and loricrin; Covance, Richmond, CA), anti-Protein kinase C a and antiphospho-PKCa (Santa Cruz Biotechnology, Santa cruz, CA). Protein bands were visualized using the enhanced chemiluminescence detection kit (GE Healthcare, Piscataway, NJ).
Immunohistochemistry Serial 6 lm thick sections were prepared and immunohistochemistry was done using the ABC and DAB kits from Vector Laboratories (Burlingame, CA). Skin was immunostained with goat anti-CD31 (1:200; Santa Cruz Biotechnology) and rabbit anti-cytokeratin antibodies (1:2000; DAKO diagnostics). Histological sections were photographed using an Olympus AX70 microscope (Olympus Optical Center Valley, PA) with analysis software (Soft Imaging System, Center Valley, PA).
Apoptosis, protein kinase and phosphoprotein screening Whole-skin lysate from mice (0.5 mg) was prepared as described previously (24) . The Kinetworks TM apoptosis (KAPS-1.0), phosphosite (KPSS-1.3) and protein kinase (KPKS-1.2) screens were performed by Kinexus Bioinformatics (Vancouver, BC) (25) .
Results
Regulated expression of activated H-Ras V12G in the skin basal epidermis was achieved by producing a mouse containing two transgenes. One transgene expresses the tetracycline transactivator under the control of the bovine keratin 5 gene promoter (K5-tTA) that is active in the basal epidermis of the skin both in utero and in the adult. The second transgene contains the oncogenic H-Ras V12G gene driven by a minimal promoter containing seven DNA-binding sites for the tetracycline transactivator (tetO-H-Ras V12G ). Crosses between K5-tTA and tetO-H-Ras V12G mice did not produce any double-transgenic pups, indicating that K5-driven expression of activated H-Ras V12G in utero is lethal. However, if the mothers were fed Dox in the food to suppress H-Ras V12G expression during development, double-transgenic K5:H-Ras V12G mice were born at the expected Mendelian frequencies. These double-transgenic mice develop like their wild-type littermates when continually fed Dox in the food.
H-Ras V12G expression was induced at 30 days by feeding K5:H-Ras V12G double-transgenic mice food without Dox. All the double-transgenic but none of the single-transgenic mice (either K5 or tetO-H-Ras V12G mice) developed a wide variety of epithelial alterations, ranging from benign skin hyperplasia to dysplasia, alopecia, keratinous cysts ( Figure 1B and 2A) and swelling of the salivary glands (data not shown) that are consistent with other groups findings (5,26). However, we did not observe any macro abnormality of other organs (i.e. oral mucosa, tongue, esophagus, uterine cervix and fore stomach) as reported by Vitale-Cross et al. (5) . Massive angiogenesis was also observed in the skin ( Figure  1F ). Twenty-one days after H-Ras V12G expression was induced, expression was suppressed by using food containing 200 mg/kg Dox. This allowed us to examine the dependence of the skin phenotype on continual H-Ras V12G expression. The expression of H-Ras V12G protein was suppressed in the skin after 3 days ( Figure 1A ). After 10 days, mouse skin showed intermediate phenotype. Finally, the skin appearance returned to near normal after 30 days ( Figure 1C -E). Compared with HRas V12G -expressing skin ( Figure 2A ; left panel), dramatic histological changes in the skin were observed at day 3 after suppression of HRas V12G protein ( Figure 2A ; right panel) and the skin histology became normal after 30 days ( Figure 2C ). However, in the presence of Dox when H-Ras V12G is not expressed, wild-type (supplementary figure is available at Carcinogenesis Online) and K5:H-Ras V12G ( Figure 2B ) skins were histologically indistinguishable, indicating the tight control of oncogenic H-Ras protein expression on Dox.
Histological analysis of skin during reversible H-Ras V12G expression: growth and death Three types of histological analyses of the skin revealed cellular events involved in both the H-Ras V12G -dependent skin hyperplasia Proteomic targets of H-Ras V12G de-induction and the subsequent regression following H-Ras V12G de-induction. These analyses included: (i) hematoxylin-and eosin-stained sections to examine general tissue histology, (ii) BrdU labeling and immunohistological staining to identify cells undergoing cell proliferation and (iii) terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) analysis to identify cells undergoing apoptosis. The dorsal skin of H-Ras V12G -expressing ( Figure 2C -E) and wild-type (supplementary figure is available at Carcinogenesis Online) mice was examined at eight time points. Four time points were 0, 3, 7 and 21 days of H-Ras V12G expression. Four additional time points examined the consequences of H-Ras V12 suppression for 3, 7, 14 and 30 days after being expressed for 21 days. The quantification of cell growth and apoptosis during this time course is presented for both the K5:H-Ras V12G and wild-type mice ( Figure 2F and G).
The induction of H-Ras V12G expression resulted in hyperproliferation of the epidermis that was evident as early as 3 days. At 7 day, the hyperplasia is more pronounced in both the basal layer of the epidermis and in the hair follicles ( Figure 2C ), something not observed in wild-type skin (supplementary figure is available at Carcinogenesis Online). At day 21, the epidermis was hyperplastic and developed keratinous cysts. BrdU-positive cells were abundant in basal cells and in cells of the cyst walls ( Figure 2D ). There were no apoptotic cells observed at either day 3 or 7 although there was a slight increase in TUNEL-positive cells at day 21 ( Figure 2E) . The de-induction of H-Ras V12G after 21 days of expression resulted in a dramatic shift from cell growth to apoptosis ( Figure 2F and G). Three days after H-Ras V12G de-induction, BrdU incorporation was not detected, whereas apoptosis, as evident by TUNEL staining, occurred primarily in the stromal cells that do not express H-Ras V12G . In some sections, the entire region of stroma underwent apoptosis. In addition, apoptotic cells also appeared in the suprabasal cells of the epidermis. On day 14 of H-Ras V12G de-induction, apoptosis was lower while proliferating cells became detectable in the hair follicles. At this time, many of hair follicles were in the anagen phase as a part of skin recovery.
To identify if the apoptotic cells are epidermal in origin, serial sections of skin were stained using a pan-keratin antibody to detect epidermis cells and a CD31 antibody to detect endothelial cells. Within 3 days of H-Ras V12G de-induction, apoptotic cells were observed that are pan-keratin negative (Figure 3A and C; left panel). They are near CD31-positive cells adjacent to blood vessels ( Figure  3A and B; left panel). In addition, VEGF protein was strongly expressed in H-Ras V12G -expressing skin, but completely disappeared within one week of H-Ras V12G de-induction ( Figure 3D ). The significant apoptotic rate of cells lining tumor vessels suggests that continued H-Ras V12G expression is required for the critical host-tumor symbiotic interaction that sustains stable tumor vasculature and is consistent with the reports that K-and H-Ras V12G can stimulate VEGF expression (27) . Apoptotic cells were also detected in epidermal cells expressing keratin protein (Figure 3A and C; right panel).
Increase in pro-apoptotic proteins without effecting the expression of differentiation markers in H-Ras V12G -suppressing skin It has been reported previously that tumor regression upon oncogene de-induction is due to apoptosis and differentiation (28) . To identify molecular pathways involved in the induction of apoptosis in skin after H-Ras V12G de-induction, the Kinetworks TM Apoptosis Protein Screen (KAPS-1.0) that determines protein levels of 25 candidate apoptosis proteins (Figure 4 ) was used.
The induction of H-Ras V12G for 3 weeks increased concentrations of several proteins including the procaspases (proCASP1a, pro-CASP3, CASP5 int and proCASP12) and decreased concentrations of others including CytoC, Fas and CASP5 p20, a matured form of procaspase 5 ( Figure 4D ). The increase in procaspase level in H-Ras V12G -expressing human ovarian cancer model has been described earlier (29) .
When H-Ras V12G is de-induced, the four procaspases that were most strongly induced by H-Ras V12G expression decreased to below wild-type levels. In contrast, several proteins that are pro-apoptotic were induced including AIF, Fas and FasL ( Figure 4D ). Bax protein, which induces the releases of mitochondrial AIF and is a member of Bcl-2 protein family (30), increased over 3-fold in mice after H-Ras V12G de-induction ( Figure 4E ).
To evaluate if the observed apoptosis coincided with cell differentiation as occurs in normal skin (31), we examined the levels of differentiation markers such as keratin 1, keratin 10, involucrin and loricrin. These markers increased with H-Ras V12G expression but decreased after H-Ras V12G suppression, indicating that the observed apoptosis was not part of the normal differentiation program ( Figure 4F ).
Phosphoprotein changes in skin after reversible H-Ras V12G expression Ras act via downstream effectors cascades to alter cellular growth and apoptosis (32) . To identify kinases and protein phosphorylation changes that accompany H-Ras V12G activation and subsequent suppression, we used four Kinetworks TM multi-immunoblotting screens to examine the phosphorylation of 37 proteins and expression levels of 75 protein kinases.
We first utilized a Kinetworks TM Phospho-Site Screen (KPSS-1.3) to identify changes in the phosphorylation status of 37 protein phosphorylation sites after H-Ras V12G expression in the three skin samples described above ( Figure 5A and C) . These results are summarized in Figure 5D organized to show the most striking increases in protein phosphorylation at the top and the largest decreases at the bottom of the bar graph. It should be appreciated that the most reliable results are provided when the intensity of the enhanced chemiluminescence signals from the immunoblots are higher. Figure 5D reveals that several known downstream effectors of H-Ras V12G including RSK1 (10-fold), STAT3 (9-fold) and MEK1 (3.5-fold) have increased phosphorylation levels following H-Ras V12G expression. Other proteins, not previously associated with Ras activation, such as NR1 and nucleophosmin (B23), had over a 2-fold increase in their phosphorylation levels. Decreased phosphorylation is observed with adducin a and c, CREB1, p38 mitogen activating protein (MAP) kinase and c-jun N-terminal kinase. cAMP response element binding protein (CREB) does not show increased phosphorylation even though it is a direct target of RSK1, which is induced 10-fold (33) .
Following H-Ras V12G de-induction, the phosphorylation states of many proteins returned to normal (Raf1, MEK1 and B23). However, several proteins had increased phosphorylation (adducina/c, S6Ka/2, PKCa/b/e, GSK3a/b) and may mediate the increased apoptosis observed as the hyperplasic state reverts to a normal.
Protein kinase changes in skin after reversible H-Ras V12G expression To evaluate the consequences of H-Ras V12G induction and de-induction on protein kinase expression levels, we employed a Kinetworks TM Figure 5E ). When H-Ras V12G is de-induced, only three (Pak3, BMX and S6Ka/ b) of the seven kinases that increase 3-fold revert to near normal, whereas CDK4 concentration actually increases. Several additional kinases also increase with H-Ras V12G de-induction (ZIPK, CaMK4, CaMKK, focal adhesion kinase (FAK) and PKCd/e) ( Figure 5E ).
The protein kinase screen ( Figure 5E ) and the phosphoprotein screen ( Figure 5D ) contain signals for 16 common proteins allowing one to determine if the fraction of protein that is phosphorylated changes in the different samples. The stoichiometry of phosphorylation (the ratio of total phospho-site signal divided by the total protein signal) was substantially reduced with H-Ras V12G de-induction for Raf1 (by 54%), MEK1 (by 76%), ERK2 (by 55%), GSK3b (by 54%) and PKCd (by 55%). In contrast, H-Ras V12G de-induction increases the stoichiometry of phosphorylation for S6Ka/b T389 (by .1000%) and Rsk 1/3 T359þS363/T356þS360 (by 330%), but there was a compensatory reduction in the total protein levels of these kinases at the same time.
Reversible morphological changes following H-Ras V12G suppression in primary keratinocytes
To determine if the reversibility observed in adult mice skin after H-Ras V12G suppression was also observed in cell culture, we prepared primary keratinocytes cultures from the K5:H-Ras V12G newborn pups. Two days after induction of H-Ras V12G expression in primary keratinocytes, distinct morphological changes were observed including swollen cytoplasm with vacuoles. Nine days of H-Ras V12G expression causes dramatic morphological changes ( Figure 6A ; upper panel). These morphological changes were totally reversed within 7 days after suppression of H-Ras V12G expression ( Figure 6A ; lower panel). We also found that expression of H-Ras V12G protein was dramatically decreased within 5 days after addition of Dox ( Figure 6B ). To confirm the skin-screening results, we examined the levels of PKCa in the keratinocytes. Compared with H-Ras V12G -expressing keratinocytes, the phosphorylation of PKCa protein dramatically increased .5-fold on day 5 after H-Ras V12G suppression and then decreased on day 7 ( Figure 6B ). However, compared with H-Ras-expressing keratinocytes, total PKCa protein level was not significantly different in the H-Ras V12G -suppressed keratinocytes ( Figure 6B ).
Discussion
We present for the first time a histological and proteomic examination of the reversible expression of oncogenic H-Ras V12G in the mouse epidermis under keratin 5 promoter control. This study shows that the H-Ras V12G -induced epidermal hyperplasia is reversible after H-Ras V12G de-induction, a process that involves apoptosis in both the stroma and the suprabasal cells of the epidermis. The massive induction of apoptosis in the stroma within day 3 of H-Ras V12G suppression occurred near blood vessels in an ''all or none'' type pattern. These results indicate that H-Ras V12G expression is needed in a non-cell-autonomous (paracrine) manner to maintain the non-HRas V12G -expressing cells. Apoptosis also occurred in the suprabasal To initiate a molecular characterization of this poorly understood phenomenon of cell death induced by oncogene withdrawal, we have identified changes in protein expression and phosphorylation status in the skin following H-Ras V12G de-induction. These proteins are potential biomarkers and molecular mediators of oncogenic addiction. Oncogenic dependence or oncogenic addiction is a term used to describe the observation that tumors initiated by oncogene expression are dependent on their continual expression for tumor stability (20, 21) . When the oncogene is de-induced, the tumors swiftly regress mainly by apoptosis or differentiation. For example, H-Ras V12G -induced mouse melanomas regressed via apoptosis when H-Ras V12G expression was suppressed (17) or partially regress when K-Ras is suppressed in lung cancers (34) . A similar reversal of the tumor phenotype via apoptosis is observed when the expression of the c-Myc oncogene (18) or mutant EGF receptor (19) is de-induced. However, this phenomenon has never been described in the epidermis.
The induction of apoptosis in the stroma where H-Ras V12G is not expressed suggests a paracrine function for cells that express H-Ras V12G . One of these proteins could be the secreted VEGF that is up-regulated by H-Ras V12G induction in skin and substantially downregulated when H-Ras V12G is suppressed (Figure 3) . Down-regulation of VEGF following H-Ras V12G suppression is also observed in melanocytes (17) . In that study, forced expression of VEGF was not sufficient to reverse the induction of apoptosis when H-Ras V12G was de-induced, suggesting that additional H-Ras V12G targets are critical for the induction of apoptosis in melanomas.
Using the Kinetworks apoptosis protein screen (KAPS-1.0) (Figure 4 ), expression profiles of number of apoptotic proteins were studied.
Several procaspases (1a, 3, 5 and 12) that were induced following H-Ras V12G induction decreased or disappeared in the skin after H-Ras V12G de-induction as the skin switches from cell growth to apoptosis (Figure 4) . Several pro-apoptotic proteins increased including Bax and Apoptosis inducing factor (AIF) involved in the intrinsic apoptosis pathway and FAS and FAS ligand involved in the extrinsic apoptosis pathway (35) . An increase in AIF level suggests that a caspase-independent mechanism may also play a role to induce apoptosis. However, unlike the previous reports showed that marked differentiation in oncogene inactivation (18, 36) , H-Ras V12G -suppressing skin did not show any increase in differentiation (Figure 4 ), suggesting that differentiation may not be a contributing factor in reversible phenotype.
The molecular changes that accompany tumor regression when the activating oncogene is de-induced have not previously been described. To begin to address this issue, we investigated protein changes in the skin after H-Ras V12G induction and subsequent de-induction. We examined the phosphorylation status of 37 phosphoproteins and the expression levels of 75 protein kinases. The proteomic analysis examined the entire skin and describes a global change in protein concentrations, whereas our histological analysis identified apoptosis in two distinct cell populations following H-Ras V12G suppression, the stroma and the suprabasal epidermis. Future studies will address where in the skin these proteomic changes occur.
Targets of H-Ras V12G activity that induce cell proliferation are readily identifiable in the hyperplastic skin. These include phosphorylation of several well-known downstream effectors of Ras signaling via Raf1, including Raf1 itself, MEK1, RSK1 and STAT3. There was also a decrease in the phosphorylation of MEK6 and its target p38 MAP kinase as well as c-jun N-terminal kinase MAP kinase following H-Ras V12G induction ( Figure 5 ) consistent with repression of the inhibitory roles that these protein kinases normally play in cell proliferation and their pro-apoptotic functions. In contrast, extracellular signal-regulated kinase phosphorylation was not changed much in H-Ras V12G -induced skin ( Figure 5D ). With H-Ras V12G suppression, there was a complete loss of protein serine phosphatase 4-A#2 expression and a reduction of protein serine phosphatase 4-C levels to even below the wild-type values. In contrast, H-Ras V12G suppression also caused even more marked increases in the expressions of MAP kinase phosphatase 2. The finding that the concentrations of diverse protein phosphatases were also markedly altered with the gain of Ras function as well as its subsequent repression adds an extra dimension to the complexity in interpreting the observed changes in protein phosphorylation. The induction of the dual specificity MAP kinase phosphatase may partly account for why the phosphorylation levels of ERK1 and ERK2 were not significantly affected in the skin of H-Ras V12G -expressing and repressed animals, despite the increases in expression and activating phosphorylation of the upstream kinase MEK1. When H-Ras V12G is de-induced, signaling pathways upstream of the apoptotic machinery (discussed above) also changes. These changes have previously been shown to have either anti-apoptotic or pro-apoptotic consequences. Anti-apoptotic signals are increased phosphorylation of the a and b subunits of S6K that increase ribosomal translation. An additional anti-apoptotic signal is the increase in FAK protein, a kinase involved in organizing stress fibers in cell culture (38) .
Several pro-apoptotic changes are evident. These include decreased phosphorylation of Akt1, a survival factor, which has also been shown to respond to VEGF to promote endothelial cell survival (39) , thus contributing to apoptosis in the stroma. In addition, an increase in p38 MAP kinase phosphorylation level (40) and ZIP kinase protein after H-Ras V12G de-induction is consistent with previously reported work (41) .
Proapoptotic signals that increase include phosphorylation of PKCa/b and PKCe. PKCs promote apoptosis in human gastric cancer cells (42) and mouse keratinocytes (43) . Our studies indicate PKCa activation after H-Ras V12G suppression could also contribute to cell killing that is often required before the recovery process. The result showing that the phosphorylation of PKCa decreased in H-Ras V12G -expressing skin ( Figure 5D ) was consistent with the previous reports that down-regulation of PKC protein level and activity are seen in cells expressing activated Ras genes (44) (45) (46) (47) (48) . ''Adducin a/c that are the targets of phoshorylated PKC also increases, leading to waning of cell-cell interactions and apoptosis 49''. Furthermore, the phenotypic reversibility and an increase in PKCa phosphorylation also occurred in the primary keratinocytes system after H-Ras V12G suppression (Figure 6 ), indicating that it is a cell-autonomous property. More work will be needed to determine if these pathways are active in apoptotic cells. Interestingly, in primary keratinocytes cell culture (Figure 6 ), the significant apoptotic event did not occur in the reversible manner upon H-Ras suppression (data not shown), suggesting the possibility that the reversibility following Dox addition may reflect a continued requirement for H-Ras in promoting and sustaining cell-autonomous hyperplasia-host interactions that are essential for the skin phenotype and maintenance that are not faithfully mimicked in tissue culture.
In summary, we have identified protein and phosphoprotein changes that accompany H-Ras V12G induction and de-induction in mouse skin. These molecular changes may mediate the poorly understood phenomenon of oncogenic addiction.
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